Provectus Biopharmaceuticals annual total debt
2017
2019
2020
2021
2022
2023
2024
2025
Provectus Biopharmaceuticals Total Debt Growth & History (PVCT)
Provectus Biopharmaceuticals's total debt was $127,304 for fiscal 2025.
View full Provectus Biopharmaceuticals company overviewProvectus Biopharmaceuticals annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $127,304 | $102,005 | +403.20% |
| 2024 | 2024-12-31 | $25,299 | −$848,078 | −97.10% |
| 2023 | 2023-12-31 | $873,377 | $130,579 | +17.58% |
| 2022 | 2022-12-31 | $742,798 | −$562,819 | −43.11% |
| 2021 | 2021-12-31 | $1.3M | −$15.4M | −92.21% |
| 2020 | 2020-12-31 | $16.8M | $16.0M | +2269.06% |
| 2019 | 2019-12-31 | $707,081 | — | — |
| 2017 | 2017-12-31 | $4.5M | — | — |
Provectus Biopharmaceuticals quarterly total debt
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $103,900 | −$46,232 | −30.79% |
| Q1 2026 | 2026-03-31 | $115,674 | $102,945 | +808.74% |
| Q4 2025 | 2025-12-31 | $127,304 | $102,005 | +403.20% |
| Q3 2025 | 2025-09-30 | $138,789 | $101,075 | +268.00% |
| Q2 2025 | 2025-06-30 | $150,132 | $100,157 | +200.41% |
| Q1 2025 | 2025-03-31 | $12,729 | −$49,020 | −79.39% |
| Q4 2024 | 2024-12-31 | $25,299 | −$848,078 | −97.10% |
| Q3 2024 | 2024-09-30 | $37,714 | −$822,146 | −95.61% |
| Q2 2024 | 2024-06-30 | $49,975 | −$121,227 | −70.81% |
| Q1 2024 | 2024-03-31 | $61,749 | −$620,319 | −90.95% |
| Q4 2023 | 2023-12-31 | $873,377 | $130,579 | +17.58% |
| Q3 2023 | 2023-09-30 | $859,860 | −$1.1M | −55.64% |
| Q2 2023 | 2023-06-30 | $171,202 | −$1.8M | −91.22% |
| Q1 2023 | 2023-03-31 | $682,068 | −$646,135 | −48.65% |
| Q4 2022 | 2022-12-31 | $742,798 | −$562,819 | −43.11% |
| Q3 2022 | 2022-09-30 | $1.9M | — | — |
| Q2 2022 | 2022-06-30 | $1.9M | $1.9M | +2140.74% |
| Q1 2022 | 2022-03-31 | $1.3M | −$16.6M | −92.60% |
| Q4 2021 | 2021-12-31 | $1.3M | −$15.4M | −92.21% |
| Q2 2021 | 2021-06-30 | $86,974 | −$16.0M | −99.46% |
| Q1 2021 | 2021-03-31 | $18.0M | $16.8M | +1411.87% |
| Q4 2020 | 2020-12-31 | $16.8M | $16.0M | +2269.06% |
| Q3 2020 | 2020-09-30 | $16.6M | $16.4M | +7295.86% |
| Q2 2020 | 2020-06-30 | $16.0M | $15.8M | +6499.43% |
| Q1 2020 | 2020-03-31 | $1.2M | $926,564 | +354.95% |
| Q4 2019 | 2019-12-31 | $707,081 | — | — |
| Q3 2019 | 2019-09-30 | $225,067 | −$6.8M | −96.79% |
| Q2 2019 | 2019-06-30 | $243,053 | −$6.2M | −96.21% |
| Q1 2019 | 2019-03-31 | $261,039 | −$4.9M | −94.94% |
| Q3 2018 | 2018-09-30 | $7.0M | $3.9M | +126.19% |
| Q2 2018 | 2018-06-30 | $6.4M | $3.9M | +151.45% |
| Q1 2018 | 2018-03-31 | $5.2M | $2.7M | +106.48% |
| Q4 2017 | 2017-12-31 | $4.5M | — | — |
| Q3 2017 | 2017-09-30 | $3.1M | — | — |
| Q2 2017 | 2017-06-30 | $2.5M | — | — |
| Q1 2017 | 2017-03-31 | $2.5M | — | — |
Provectus Biopharmaceuticals total debt trends
Over the last five fiscal years, Provectus Biopharmaceuticals's total debt decreased from $16.8M to $127,304, a change of −$16.6M. The latest reported quarter, Q2 2026, shows $103,900.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Provectus Biopharmaceuticals source filings ↗